Most patients receiving a GLP-1 receptor agonist (RA) and a biologic continue co-therapy for over a year with few treatment-related adverse events.

INTENT Biologics, a clinical-stage biotechnology company developing PEP Biologic as the first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, ...

Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...

The idea that mental disorders are caused by a biological mechanism is linked with prolonged use of antidepressants and ...

Pregnant women who take biologic medication for rheumatoid arthritis are not running the risk of their infant developing serious/opportunistic infections, according to research presented at the 2017 ...

If you have moderate to severe ulcerative colitis (UC) and haven’t found enough relief from traditional medications, your doctor may talk to you about biologics. These newer drugs, which include ...

Bimekizumab exhibited superior drug survival rates among patients with psoriasis who have previously stopped responding to at ...

Tumour necrosis factor (TNF) inhibitors are more likely discontinued due to ineffectiveness in patients aged 16-24 years than in those aged 45-54 years. However, patients aged ≥ 75 years have an ...

A 46-year-old man presents for his first dermatology consultation for worsening symptoms of plaque psoriasis and recent-onset joint pain. He reports “painful aching” and swelling of his finger joints, ...

Becton, Dickinson and Company BDX, popularly known as BD, recently announced the expansion of its partnership with Ypsomed to ...

A major American medical device manufacturer is investing $110 million to expand production in Nebraska as part of an effort ...